- Home
- ACXP vs ALZN Comparison
ACXP vs ALZN Comparison
Compare ACXP & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- ALZN
- Stock Information
- Founded
- ACXP 2017
- ALZN 2016
- Country
- ACXP United States
- ALZN United States
- Employees
- ACXP 4
- ALZN N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- ACXP Health Care
- ALZN Health Care
- Exchange
- ACXP Nasdaq
- ALZN Nasdaq
- Market Cap
- ACXP 6.8M
- ALZN 7.4M
- IPO Year
- ACXP 2021
- ALZN 2021
- Fundamental
- Price
- ACXP $4.29
- ALZN $2.41
- Analyst Decision
- ACXP Strong Buy
- ALZN Strong Buy
- Analyst Count
- ACXP 3
- ALZN 1
- Target Price
- ACXP $143.67
- ALZN $45.00
- AVG Volume (30 Days)
- ACXP 73.5K
- ALZN 65.0K
- Earning Date
- ACXP 11-12-2025
- ALZN 09-10-2025
- Dividend Yield
- ACXP N/A
- ALZN N/A
- EPS Growth
- ACXP N/A
- ALZN N/A
- EPS
- ACXP N/A
- ALZN N/A
- Revenue
- ACXP N/A
- ALZN N/A
- Revenue This Year
- ACXP N/A
- ALZN N/A
- Revenue Next Year
- ACXP N/A
- ALZN N/A
- P/E Ratio
- ACXP N/A
- ALZN N/A
- Revenue Growth
- ACXP N/A
- ALZN N/A
- 52 Week Low
- ACXP $3.80
- ALZN $2.06
- 52 Week High
- ACXP $44.00
- ALZN $19.08
- Technical
- Relative Strength Index (RSI)
- ACXP 38.73
- ALZN 47.08
- Support Level
- ACXP $4.02
- ALZN $2.30
- Resistance Level
- ACXP $4.27
- ALZN $2.45
- Average True Range (ATR)
- ACXP 0.53
- ALZN 0.11
- MACD
- ACXP 0.10
- ALZN 0.02
- Stochastic Oscillator
- ACXP 13.86
- ALZN 60.60
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.